spin ph online casino

spin ph online casino

No. 2 Ohio State takes control in the 2nd half and runs over No. 5 Indiana 38-15'Decades' for ex-coal sites to be safe to go nuclear

Mercedes-Benz Group ( OTCMKTS:MBGYY – Get Free Report ) is one of 76 public companies in the “Motor vehicles & car bodies” industry, but how does it contrast to its rivals? We will compare Mercedes-Benz Group to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability. Insider & Institutional Ownership 45.3% of shares of all “Motor vehicles & car bodies” companies are owned by institutional investors. 12.1% of shares of all “Motor vehicles & car bodies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Earnings and Valuation This table compares Mercedes-Benz Group and its rivals revenue, earnings per share and valuation. Analyst Ratings This is a breakdown of current ratings and recommmendations for Mercedes-Benz Group and its rivals, as reported by MarketBeat.com. As a group, “Motor vehicles & car bodies” companies have a potential upside of 3.14%. Given Mercedes-Benz Group’s rivals higher probable upside, analysts clearly believe Mercedes-Benz Group has less favorable growth aspects than its rivals. Profitability This table compares Mercedes-Benz Group and its rivals’ net margins, return on equity and return on assets. Risk & Volatility Mercedes-Benz Group has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Mercedes-Benz Group’s rivals have a beta of 3.47, suggesting that their average stock price is 247% more volatile than the S&P 500. Summary Mercedes-Benz Group rivals beat Mercedes-Benz Group on 7 of the 13 factors compared. Mercedes-Benz Group Company Profile ( Get Free Report ) Mercedes-Benz Group AG operates as an automotive company in Germany and internationally. It operates through Mercedes-Benz Cars, Mercedes-Benz Vans, and Mercedes-Benz Mobility segments. The company develops, manufactures, and sells cars and vans under the Mercedes-Benz, Mercedes-AMG, Mercedes-Maybach, G-Class brands, as well as related spare parts and accessories. It also provides financing, leasing, car subscription and rental, fleet management, insurance brokerage, and mobility services, as well as digital services for charging and payment. The company was formerly known as Daimler AG and changed its name to Mercedes-Benz Group AG in February 2022. Mercedes-Benz Group AG was founded in 1886 and is headquartered in Stuttgart, Germany. Receive News & Ratings for Mercedes-Benz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mercedes-Benz Group and related companies with MarketBeat.com's FREE daily email newsletter .Ben Wikler chairs Wisconsin’s Democratic Party and is running for chair of the Democratic National Committee . On Monday, Wikler went on “The Daily Show” to make his case to host Jon Stewart. ”I think that we're kind of in a system that is generally broken,” Wikler said. “Money has this giant role in politics on both sides. People's attention is in a million different places. So you can scream something from the rooftops and almost no one will hear it.” Wikler proposed stepping away from big-data organizing and embracing a more grassroots approach. “We built neighborhood teams,” he said. “So neighbors are knocking on their neighbor’s door, so that it's someone that you actually know so much as to where you are. That's how we do it in Wisconsin.” x x YouTube Video As chair of the Wisconsin Democrats, Wikler earned praise for successfully fighting a Republican takeover there by getting the state Supreme Court back under Democratic control, which helped reverse GOP-rigged gerrymandering in the Badger State. Wikler’s likely opponents for DNC chair include: former Texas Rep. Beto O’Rourke; Michael Blake, a former vice chair of the DNC; and former Ambassador to Japan Rahm Emanuel. The party’s new leader will be selected in January 2025. Here’s a link to Wikler’s community account at Daily Kos, Enjoy ! Click here for Daily Kos’ Bluesky Starter Pack. Join us on Bluesky and @#$% Elon Musk!Chad Chronister, Donald Trump’s pick to run the DEA, withdraws name from consideration

Pitt quarterback Eli Holstein leaves game with left leg injury against Louisville

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. FATE , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation," said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization." FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ", the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ", the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.The 2024 NBA Cup will finish its group stage component on Tuesday with 11 games. Among those 11 games, only three are completely devoid of stakes. The 76ers and Hornets , Wizards and Cavaliers , and 76ers and Pacers have all been mathematically eliminated from advancing to the knockout stage. However, that leaves eight games left on the slate in which there are meaningful stakes for at least one of the teams involved. Some of them are obviously more meaningful than others. In the Eastern Conference, for example, we have two head-to-head clashes among undefeated teams that will decide group winners. Other games feature only point-differential consequences, or have only one team that is still eligible to advance. But, in short, eight of these 11 games matter on some level. So let's go through those games. Below, we'll cover when those games tip, where you can watch them, what the stakes are for each, and make one best bet per game. Most of Tuesday's games are also available streaming locally on fubo (Try for free). All odds below are from BetMGM . Fans can take action on the NBA Cup by using the latest BetMGM promo code . Milwaukee Bucks at Detroit Pistons Start time: 7 p.m. ET Where to watch: NBA League Pass The stakes: Winner wins East Group B. Loser could potentially be the Eastern Conference wild-card team. Best bet: Let's keep this one simple. The Bucks have won six straight. Giannis Antetokounmpo is averaging a robust 34.4 points, 11 rebounds and eight assists during the streak. The Pistons have a good rim defense, but there is no defense for Antetokounmpo right now. The streak keeps rolling. The Pick: Bucks -3.5 Orlando Magic at New York Knicks Start time: 7:30 p.m. ET Where to watch: TNT The stakes: Winner wins East Group A. Loser could potentially be the Eastern Conference wild-card team. If New York wins a close game, Orlando, by virtue of its enormous point-differential advantage (at +60, 30 points higher than any other Eastern Conference team) is likely to be the Eastern Conference wild-card team. Best bet: In this game we have an unstoppable force (New York's No. 1 rated offense) against an immovable object (Orlando's No. 3 ranked defense). When Jalen Brunson ran into that immovable object last season, he shot 4-of-15 and scored 20 points in a loss in the lone game both he and Jalen Suggs played in. Suggs is healthy, so expect him to continue causing problems for Brunson this time around. The Pick: Brunson Under 23.5 Points Utah Jazz at Oklahoma City Thunder Start time: 8 p.m. ET Where to watch: NBA League Pass The stakes: If Oklahoma City wins and San Antonio loses, Oklahoma City wins West Group B. If Oklahoma City wins and San Antonio wins, Oklahoma City could potentially be the Western Conference wild-card team. Best bet: The line here is inflated because Vegas knows that the Thunder need a high point-differential to advance. Right now, the Thunder are favored by 13.5 points, but Utah has covered that spread in 11 of its last 12 games and its only bigger loss was by just 19 against Denver. The Jazz are more competitive than their numbers indicate, at least by the standard this line sets. The Pick: Jazz +13.5 Memphis Grizzlies at Dallas Mavericks Start time: 8:30 p.m. ET Where to watch: NBA League Pass The stakes: Both the Mavericks and Grizzlies could still potentially be the Western Conference wild-card team. The path for Dallas is clean: with a 2-1 record and a +41 point-differential, it would be favored to advance with a win and could only be knocked off if another 3-1 team picked up a blowout on Tuesday. Memphis would need quite a bit of help to advance even with a win. Best bet: Luka Doncic returned from injury with a bang on Sunday, scoring 36 points and racking up 13 assists and seven rebounds in a win over Portland. Historically, this is roughly the point on the calendar in which Doncic starts to ramp up statistically. Grab his overall numbers prop. The Pick: Doncic Over 45.5 Points+Rebounds+Assists San Antonio Spurs at Phoenix Suns Start time: 9 p.m. Where to watch: NBA League Pass The stakes: If San Antonio wins, it wins West Group B. If Phoenix wins, it wins West Group B with an Oklahoma City loss. If Phoenix wins and Oklahoma City wins, the Suns are still a potential Western Conference wild-card team. Best bet: No team gets to the basket less than the Suns. The presence of Victor Wembanyama only encourages more 3-pointers. Your move here is just to pick a Suns shooter you expect to hit a bunch of 3-pointers. I'm going to take Tyus Jones , who is playing against his brother Tre Jones , but is also likeliest to have Chris Paul , the least dangerous perimeter on the Spurs, defending him when the starters are on the floor just because of how dangerous every other Suns scorer is. The Pick: Tyus Jones over 1.5 3s Golden State Warriors at Denver Nuggets Start time: 10 p.m. ET Where to watch: TNT The stakes: Golden State has already won West Group C, but its seeding in the knockout stage will depend on its overall group play record and/or point-differential depending on a variety of outcomes on Tuesday. Denver is still eligible to be the Western Conference wild-card team, but would need quite a bit of help. Best bet: I'm playing a hunch here. Stephen Curry spoke openly about the difficult players have had in finding a rhythm so far this season due to Steve Kerr's deep rotations after Saturday's loss to Phoenix. I'm expecting things to tighten up a bit for the Denver game, and one way that could manifest is more Curry minutes. I'm expecting his scoring to go up as a result. The Pick: Curry Over 23.5 Points Houston Rockets at Sacramento Kings Start time: 10 p.m. ET Where to watch: NBA League Pass The stakes: Houston has already won West Group A, but its seeding in the knockout stage will depend on its overall group play record/and or point-differential depending on a variety of outcomes on Tuesday. Best bet: Houston's stellar defense is defined by two reserves: Amen Thompson and Tari Eason , the Terror Twins. My play here is to pick an under on a Sacramento scorer likely to play a bunch of minutes against those bench lineups. Malik Monk started on Sunday, but that was his first start of the season, so I'm still comfortable taking his under and hoping he struggles against Houston's incredible bench defense. The Pick: Monk Under 15.5 Points Portland Trail Blazers at Los Angeles Clippers Start time: 10:30 p.m. ET Where to watch: NBA League Pass The stakes: Portland could still potentially be the Western Conference wild-card team, but would need some help. Best bet : James Harden's scoring has gotten the bulk of publicity over the past two games, but I'm more excited about his passing in this matchup. Donovan Clingan is out with a knee injury, and with Harden hot, I'm expecting Portland to sell out to stop him on drives. That will open up easy lob passes that the gigantic Clingan won't be around to break up. The Pick: Harden Over 9.5 Assists NBA Cup odds The eight-team NBA Cup bracket will be set after Tuesday night's action. The quarterfinals are slated for next week before the semifinals (Dec. 14) and final (Dec. 17) in Las Vegas. Here are the odds to win the competition from BetMGM sportsbook . Knicks: +500 Warriors: +500 Thunder: +550 Bucks: +650 Rockets: +650 Mavericks: +800 Magic: +800 Celtics: +1400 Suns: +1800

By MICHELLE L. PRICE NEW YORK (AP) — Chad Chronister, Donald Trump’s pick to run the Drug Enforcement Administration, said Tuesday he was withdrawing his name from consideration, becoming the second person selected by the president-elect to bow out quickly after being nominated for a position requiring Senate confirmation. Sheriff Chronister, the top law enforcement officer in Hillsborough County, Florida, said in a post on X that he was backing away from the opportunity, which he called “the honor of a lifetime.” “Over the past several days, as the gravity of this very important responsibility set in, I’ve concluded that I must respectfully withdraw from consideration,” Chronister wrote. He did not elaborate, and Trump’s transition team did not immediately respond to a message seeking comment. Chronister follows former Republican congressman Matt Gaetz , Trump’s first pick to serve as attorney general, in withdrawing his name for a post in the administration. Gaetz withdrew following scrutiny over a federal sex trafficking investigation that cast doubt on his ability to be confirmed as the nation’s chief federal law enforcement officer. Trump’s pick of Chronister for the DEA job drew backlash from conservatives, who raised concerns over his actions during the COVID-19 pandemic and his saying that his office “does not engage in federal immigration enforcement activities.” In March 2020, Chronister arrested the pastor of a megachurch who held services with hundreds of people and violated a safer-at-home order in place aimed at limiting the spread of the Covid virus. “Shame on this pastor, their legal staff and the leaders of this staff for forcing us to do our job. That’s not what we wanted to do during a declared state of emergency,” Chronister said at the time. “We are hopeful that this will be a wakeup call.” U.S. Rep. Thomas Massie, R-Ky, was among those airing public complaints, saying Chronister should be “disqualified” for the arrest. Others flagged comments Chronister made in a video about Florida’s immigration laws that he released in 2023 that circulated again online after Trump named him last weekend. Related Articles National Politics | Trump team signs agreement to allow Justice to conduct background checks on nominees, staff National Politics | President-elect Donald Trump’s lawyers urge judge to toss his hush money conviction National Politics | Democrats stick with Schumer as leader, their strategy for countering Trump is far less certain National Politics | Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs National Politics | Democrats’ outgoing chair says Trump’s win forces party to reassess how it reaches voters In the video, Chronister praised the “rich diversity” of his community and called it “a place where people from all walks of life come together.” He said it was important to note his office “does not engage in federal immigration enforcement activities. We do not target individuals based on their immigration status. That’s the authority of federal agencies.” Trump has made a sweeping crackdown on immigration a central focus of his campaign and his aims for his coming administration. Associated Press writer Adriana Gomez Licon in Fort Lauderdale, Florida contributed to this report. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular German restaurant Deutsche Ecke opens in Newport News German restaurant Deutsche Ecke opens in Newport News Second man dies in Newport News triple shooting; police still looking for suspects Second man dies in Newport News triple shooting; police still looking for suspects The latest business openings and closings in Hampton Roads The latest business openings and closings in Hampton Roads Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Williamsburg Christmas parade to feature Commanders marching band Williamsburg Christmas parade to feature Commanders marching band Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap 1 dead, 2 seriously injured in Newport News triple shooting, police say 1 dead, 2 seriously injured in Newport News triple shooting, police say New Kent wants public input on future of Makemie Woods New Kent wants public input on future of Makemie Woods The Grinch can’t steal West Point’s Christmas The Grinch can't steal West Point's Christmas Biden pardons his son Hunter despite previous pledges not to Biden pardons his son Hunter despite previous pledges not to Trending Nationally Judge accused of ‘willful misconduct’ for letting illegal immigrant escape court Trump’s talk of reducing or relocating federal workers hits home in Maryland A young Coloradan learning to live with long COVID turns to TikTok to educate about chronic illness Fruit trees and ‘generational learning’ turn this California city into a parrot paradise as temperatures drop NBC’s enhanced yard lines, field numbers for Bills-49ers snow game draw strong reactions from viewers

Avior Wealth Management LLC decreased its stake in shares of Global X Cybersecurity ETF ( NASDAQ:BUG – Free Report ) by 59.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,753 shares of the company’s stock after selling 14,392 shares during the quarter. Avior Wealth Management LLC’s holdings in Global X Cybersecurity ETF were worth $302,000 at the end of the most recent quarter. Other institutional investors also recently bought and sold shares of the company. OneDigital Investment Advisors LLC boosted its stake in Global X Cybersecurity ETF by 5.6% during the third quarter. OneDigital Investment Advisors LLC now owns 19,125 shares of the company’s stock worth $592,000 after buying an additional 1,014 shares during the period. Advisors Management Group Inc. ADV lifted its holdings in shares of Global X Cybersecurity ETF by 4.3% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 26,552 shares of the company’s stock worth $822,000 after acquiring an additional 1,105 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its stake in shares of Global X Cybersecurity ETF by 8.3% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 17,653 shares of the company’s stock worth $544,000 after purchasing an additional 1,354 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Global X Cybersecurity ETF by 25.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 202,799 shares of the company’s stock valued at $6,220,000 after purchasing an additional 40,799 shares during the last quarter. Finally, Greystone Financial Group LLC raised its position in Global X Cybersecurity ETF by 14.6% in the 3rd quarter. Greystone Financial Group LLC now owns 13,095 shares of the company’s stock worth $405,000 after purchasing an additional 1,665 shares during the period. Global X Cybersecurity ETF Price Performance Shares of NASDAQ:BUG opened at $33.52 on Friday. The firm has a market capitalization of $812.52 million, a PE ratio of 29.10 and a beta of 0.86. The business has a 50 day simple moving average of $31.49 and a two-hundred day simple moving average of $30.03. Global X Cybersecurity ETF has a 1 year low of $25.75 and a 1 year high of $34.16. Global X Cybersecurity ETF Profile The Global X Cybersecurity ETF (BUG) is an exchange-traded fund that is based on the Indxx Cybersecurity index, a modified market-cap-weighted global index of companies selected on the basis of revenue related to cybersecurity activities. BUG was launched on Oct 25, 2019 and is managed by Global X. Recommended Stories Receive News & Ratings for Global X Cybersecurity ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Cybersecurity ETF and related companies with MarketBeat.com's FREE daily email newsletter .

Swiss National Bank decreased its position in Core & Main, Inc. ( NYSE:CNM – Free Report ) by 0.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 376,500 shares of the company’s stock after selling 1,700 shares during the period. Swiss National Bank’s holdings in Core & Main were worth $16,717,000 as of its most recent filing with the Securities & Exchange Commission. Other large investors have also recently added to or reduced their stakes in the company. Lazard Asset Management LLC raised its holdings in Core & Main by 370.9% in the 1st quarter. Lazard Asset Management LLC now owns 273,561 shares of the company’s stock valued at $15,661,000 after acquiring an additional 215,472 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Core & Main by 31.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,745 shares of the company’s stock valued at $89,697,000 after acquiring an additional 375,311 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Core & Main by 35.9% in the 1st quarter. Advisors Asset Management Inc. now owns 45,940 shares of the company’s stock valued at $2,630,000 after acquiring an additional 12,139 shares in the last quarter. Rhumbline Advisers raised its holdings in Core & Main by 6.2% in the 2nd quarter. Rhumbline Advisers now owns 508,554 shares of the company’s stock valued at $24,889,000 after acquiring an additional 29,490 shares in the last quarter. Finally, Comerica Bank raised its holdings in Core & Main by 30.9% in the 1st quarter. Comerica Bank now owns 67,754 shares of the company’s stock valued at $3,879,000 after acquiring an additional 16,009 shares in the last quarter. Institutional investors and hedge funds own 94.19% of the company’s stock. Wall Street Analyst Weigh In A number of equities analysts have recently issued reports on the company. Truist Financial dropped their target price on Core & Main from $50.00 to $38.00 and set a “hold” rating for the company in a report on Thursday, September 5th. The Goldman Sachs Group dropped their target price on Core & Main from $57.00 to $50.00 and set a “neutral” rating for the company in a report on Friday, September 6th. JPMorgan Chase & Co. dropped their target price on Core & Main from $54.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, September 3rd. Royal Bank of Canada dropped their target price on Core & Main from $60.00 to $53.00 and set an “outperform” rating for the company in a report on Thursday, September 5th. Finally, Loop Capital dropped their target price on Core & Main from $64.00 to $52.00 and set a “buy” rating for the company in a report on Thursday, September 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.20. Core & Main Stock Up 1.6 % NYSE CNM opened at $45.28 on Friday. The firm has a market cap of $9.11 billion, a PE ratio of 21.67, a price-to-earnings-growth ratio of 2.92 and a beta of 1.02. Core & Main, Inc. has a one year low of $34.02 and a one year high of $62.15. The stock’s 50 day simple moving average is $44.27 and its 200 day simple moving average is $48.77. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.29 and a quick ratio of 1.34. Core & Main ( NYSE:CNM – Get Free Report ) last announced its quarterly earnings data on Wednesday, September 4th. The company reported $0.61 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.13). The firm had revenue of $1.96 billion during the quarter, compared to the consensus estimate of $2.05 billion. Core & Main had a net margin of 5.58% and a return on equity of 21.91%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.66 earnings per share. As a group, sell-side analysts forecast that Core & Main, Inc. will post 2.1 earnings per share for the current fiscal year. About Core & Main ( Free Report ) Core & Main, Inc distributes water, wastewater, storm drainage, and fire protection products and related services to municipalities, private water companies, and professional contractors in the municipal, non-residential, and residential end markets in the United States. Its products portfolio include pipes, valves, hydrants, fittings, and other products and services; storm drainage products, such as corrugated piping systems, retention basins, inline drains, manholes, grates, geosynthetics, erosion control, and other related products; fire protection products, including fire protection pipes, and sprinkler heads and devices, as well as fabrication services; and meter products, such as smart meter products, meter sets, meter accessories, installation, software, and other services. Featured Stories Want to see what other hedge funds are holding CNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core & Main, Inc. ( NYSE:CNM – Free Report ). Receive News & Ratings for Core & Main Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core & Main and related companies with MarketBeat.com's FREE daily email newsletter .

NoneThe Best Sports Watches for Athletes and Adventurers

The American Athletic Conference is the only Football Bowl Subdivision league whose championship game matchup is set: Army vs. Tulane. The final week of the regular season will determine pairings for the other eight conferences. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.